Nuevolution

What is Nuevolution?

Nuevolution is a prominent small molecule lead discovery firm established in 2001, operating out of Copenhagen, Denmark. The company is renowned for its development of Chemetics, a patented technology that merges advanced wet chemistry with molecular biology to form the pinnacle of fragment-based drug discovery methods. This innovative approach allows for the rapid creation and DNA-tagging of hundreds of millions of diverse, drug-like small molecules, as well as their efficient screening.

This process aids in the discovery of effective drug leads with unparalleled volume, quality, and speed when compared to other drug discovery methodologies. Their extensive library boasts over 1 billion small molecule compounds and synthetic biologics for screening purposes.

Nuevolution actively seeks partnership opportunities with pharmaceutical and biotech companies, and has successfully entered agreements with industry giants such as Merck & Co., Lexicon Pharmaceuticals, GlaxoSmithKline, Novartis Pharma, and Boehringer Ingelheim.

Additionally, Nuevolution has co-founded a joint venture consortium with EpiTherapeutics, ExpreS2ion Biotechnologies, and renowned Professor Kristian Helin from the University of Copenhagen's Biotech Research & Innovation Centre, focused on discovering and developing new small molecule drugs targeting epigenetic factors.

Backed by a budget of $4 million from the Danish High Technology Fund, this collaboration highlights the company's commitment to innovation. Nuevolution's achievements in leveraging Chemetics have led to identifying numerous potent and novel ligands capable of addressing significant unmet medical needs across various therapeutic areas and target classes. As a privately-held entity, Nuevolution's investor base consists of prominent Scandinavian institutional investors like Industrifonden, SEB Venture Capital, Sunstone Capital, SLS Invest, and Novo A/S.